Kontinuierliche Glukosemessung bei Menschen mit Typ-2-Diabetes ohne intensivierte Insulintherapie: eine Standortbestimmung

Zusammenfassung

Zahlreiche Studien haben den klinischen Nutzen der kontinuierlichen Glukosemessung (CGM) bei Menschen mit Typ-1-Diabetes belegt, was auch zu einer positiven Empfehlung des Gemeinsamen Bundesausschusses (GBA) für CGM-Systeme bei Menschen mit Diabetes und intensivierter Insulintherapie (ICT/Insulinpumpentherapie) geführt hat. Inzwischen liegen die Ergebnisse zahlreicher randomisierter, beobachtender und retrospektiver Studien zum Einsatz von CGM bei Menschen mit Typ-2-Diabetes und einer nicht intensivierten Insulintherapie (BOT/SIT/CT) oder einer Therapie ohne Insulin vor. In diesem Artikel wird die aktuelle Evidenz zum Einsatz von CGM bei diesen Patientengruppen zusammengefasst und diskutiert. Die Ergebnisse dieser Studien deuten darauf hin, dass CGM auch bei Menschen ohne intensivierte Insulintherapie wirksam ist, um die glykämische Kontrolle zu verbessern und mögliche Nebenwirkungen der Insulintherapie (Hypoglykämien) zu vermeiden.

Abstract

Several studies have shown the clinical advantages of continuous glucose monitoring (CGM) in individuals with type 1 diabetes. As a result, the Joint Federal Committee (GBA) has recommended CGM systems for individuals with diabetes and intensified insulin therapy (ICT)/insulin pump therapy. Numerous randomized, observational, and retrospective studies have been conducted on the use of CGM in people with type 2 diabetes and non-intensified insulin therapy (BOT/SIT/CT) or therapy without insulin. This article provides a summary and discussion of the current evidence on the use of CGM in these patient groups. The studies indicate that CGM is effective in improving glycemic control and avoiding potential side effects of insulin therapy, such as hypoglycemia, even in individuals without intensified insulin therapy.

Schlüsselwörter

CGM - Typ 2 Diabetes - kontinuierliche Glukosemessung - intensivierte Insulintherapie - Basalinsulin unterstützte orale antidiabetische Therapie

Keywords

CGM - Type 2 diabetes - Continuous glucose monitoring - multiple daily injections - Basal insulin supplemented oral antidiabetic therapy

Publikationsverlauf

Eingereicht: 01. Februar 2024

Angenommen nach Revision: 07. Mai 2024

Artikel online veröffentlicht:
21. Mai 2024

• Literatur

• 1 Deutsche Diabetes Gesellschaft (DDG) und diabetesDE – Deutsche Diabetes-Hilfe. Deutscher Gesundheitsbericht Diabetes. 2023
• 2 KVNO. Qualitätsbericht 2021 Disease-Management-Programme in Nordrhein. 2021
• 3 Mateo JF, Gil-Guillén VF, Mateo E. et al. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. International journal of clinical practice 2006; 60: 422-428
• 4 Khunti K, Nikolajsen A, Thorsted BL. et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes, obesity & metabolism 2016; 18: 401-409
• 5 Seidu S, Than T, Kar D. et al. Therapeutic inertia amongst general practitioners with interest in diabetes. Primary care diabetes 2018; 12: 87-91
• 6 Paul SK, Klein K, Thorsted BL. et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular diabetology 2015; 14: 100
• 7 Kaewbut P, Kosachunhanun N, Phrommintikul A. et al. Time to Treatment Intensification to Reduce Diabetes-Related Complications: A Post Hoc Study. Healthcare (Basel) 2022; 10
• 8 Cappon G, Vettoretti M, Sparacino G. et al. Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications. Diabetes Metab J 2019; 43: 383-397
• 9 Kluemper JR, Smith A, Wobeter B. Diabetes: the role of continuous glucose monitoring. Drugs Context 2022; 11
• 10 Rivera-Ávila DA, Esquivel-Lu AI, Salazar-Lozano CR. et al. The effects of professional continuous glucose monitoring as an adjuvant educational tool for improving glycemic control in patients with type 2 diabetes. BMC endocrine disorders 2021; 21: 79
• 11 Miller EM. Using Continuous Glucose Monitoring in Clinical Practice. Clinical diabetes : a publication of the American Diabetes Association 2020; 38: 429-438
• 12 Battelino T, Danne T, Bergenstal RM. et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019; 42: 1593-1603
• 13 van den Boom L, Auzanneau M, Woelfle J. et al. Use of Continuous Glucose Monitoring in Pump Therapy Sensor Augmented Pump or Automated Insulin Delivery in Different Age Groups (0.5 to <26 Years) With Type 1 Diabetes From 2018 to 2021: Analysis of the German/Austrian/Swiss/Luxemburg DPV Registry. J Diabetes Sci Technol 2023;
• 14 Deutsche Diabetes Gesellschaft (DDG): S3-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. 2023
• 15 Weitgasser R, Ciardi C, Traub J. et al. Diabetes education and counseling in adult patients with diabetes (Update 2023). Wien Klin Wochenschr 2023; 135: 137-142
• 16 Bundesärztekammer (BÄK) KBK, Arbeitsgemeinschaft der Wissenschaftli-, (AWMF) cMF. Nationale VersorgungsLeitlinie Typ-2-Diabetes – Langfassung. Version 3.0. 2023
• 17 Powers MA, Bardsley JK, Cypress M. et al. Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care 2020; 43: 1636-1649
• 18 Chatterjee S, Davies MJ, Heller S. et al. Diabetes structured self-management education programmes: a narrative review and current innovations. The Lancet Diabetes & Endocrinology 2018; 6: 130-142
• 19 Tamhane S, Rodriguez-Gutierrez R, Hargraves I. et al. Shared Decision-Making in Diabetes Care. Current diabetes reports 2015; 15: 112
• 20 Beck RW, Riddlesworth TD, Ruedy K. et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Annals of internal medicine 2017; 167: 365-374
• 21 Yaron M, Roitman E, Aharon-Hananel G. et al. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care 2019; 42: 1178-1184
• 22 Kröger J, Fasching P, Hanaire H. Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders 2020; 11: 279-291
• 23 Haak T, Hanaire H, Ajjan R. et al. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes therapy : research, treatment and education of diabetes and related disorders 2017; 8: 55-73
• 24 Vigersky RA, Fonda SJ, Chellappa M. et al. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 2012; 35: 32-38
• 25 Martens T, Beck RW, Bailey R. et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. Jama 2021; 325: 2262-2272
• 26 Bao S, Bailey R, Calhoun P. et al. Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin. Diabetes Technol Ther 2022; 24: 299-306
• 27 Davis G, Bailey R, Calhoun P. et al. Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study. Diabetes Technol Ther 2022; 24: 324-331
• 28 Aleppo G, Beck RW, Bailey R. et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care 2021; 44: 2729-2737
• 29 Yoo HJ, An HG, Park SY. et al. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes research and clinical practice 2008; 82: 73-79
• 30 Wright EE, Kerr MSD, Reyes IJ. et al. Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy. Diabetes Spectr 2021; 34: 184-189
• 31 Ajjan RA, Jackson N, Thomson SA. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. Diabetes & vascular disease research 2019; 16: 385-395
• 32 Lameijer A, Bakker JJ, Kao K. et al. Real-life 24-week changes in glycemic parameters among European users of flash glucose monitoring with type 1 and 2 diabetes and different levels of glycemic control. Diabetes research and clinical practice 2023; 201
• 33 Grace T, Salyer J. Use of Real-Time Continuous Glucose Monitoring Improves Glycemic Control and Other Clinical Outcomes in Type 2 Diabetes Patients Treated with Less Intensive Therapy. Diabetes Technol Ther 2022; 24: 26-31
• 34 Elliott T, Beca S, Beharry R. et al. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study. Diabetes & vascular disease research 2021; 18
• 35 Carlson AL, Daniel TD, DeSantis A. et al. Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis. BMJ Open Diabetes Res Care 2022; 10
• 36 Miller E, Kerr MSD, Roberts GJ. et al. Flash CGM associated with event reduction in nonintensive diabetes therapy. The American journal of managed care 2021; 27: e372-e377
• 37 Guerci B, Roussel R, Levrat-Guillen F. et al. Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France. Diabetes Technol Ther 2023; 25: 20-30
• 38 Nathanson D, Eeg-Olofsson K, Spelman T. Intermittently-scanned CGM is associated with lower HbA1c and reduced hospital admissions for adults with T2DM on insulin therapy in Sweden: a retrospective controlled study. Presented at EASD, 2 – 6 October 2023, Hamburg, Germany. 2023
• 39 Porter M, Fonda S, Swigert T. et al. Real-Time Continuous Glucose Monitoring to Support Self-Care: Results from a Pilot Study of Patients With Type 2 Diabetes. J Diabetes Sci Technol 2022; 16: 578-580
• 40 Riveline JP, Roussel R, Vicaut E. et al. Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study. Diabetes Technol Ther 2022; 24: 611-618
• 41 Roussel R, Riveline JP, Vicaut E. et al. Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Diabetes Care 2021; 44: 1368-1376
• 42 Allen NA, Fain JA, Braun B. et al. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial. Diabetes research and clinical practice 2008; 80: 371-379
• 43 Wada E, Onoue T, Kobayashi T. et al. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care 2020; 8
• 44 Cox DJ, Banton T, Moncrief M. et al. Minimizing Glucose Excursions (GEM) With Continuous Glucose Monitoring in Type 2 Diabetes: A Randomized Clinical Trial. J Endocr Soc 2020; 4: bvaa118
• 45 Aronson R, Brown RE, Chu L. et al. IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes, Obesity and Metabolism 2023; 25: 1024-1031
• 46 Polonsky WH, Soriano EC, Fortmann AL. The Role of Retrospective Data Review in the Personal Use of Real-Time Continuous Glucose Monitoring: Perceived Impact on Quality of Life and Health Outcomes. Diabetes Technol Ther 2022; 24: 492-501
• 47 Dowd R, Jepson LH, Green CR. et al. Glycemic Outcomes and Feature Set Engagement Among Real-Time Continuous Glucose Monitoring Users With Type 1 or Non-Insulin-Treated Type 2 Diabetes: Retrospective Analysis of Real-World Data. JMIR Diabetes 2023; 8: e43991
• 48 Simonson GD, Bergenstal RM, Johnson ML. et al. Effect of Professional CGM (pCGM) on Glucose Management in Type 2 Diabetes Patients in Primary Care. J Diabetes Sci Technol 2021; 15: 539-545
• 49 Jackson MA, Ahmann A, Shah VN. Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring. Diabetes Technol Ther 2021; 23: S27-s34
• 50 Vallis M, Ryan H, Berard L. et al. How Continuous Glucose Monitoring Can Motivate Self-management: Can Motivation Follow Behaviour?. Canadian journal of diabetes 2023; 47: 435-444
• 51 Gilbert TR, Noar A, Blalock O. et al. Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark Study. Diabetes Technol Ther 2021; 23: S35-s39
• 52 Bergenstal RM, Layne JEL Zisser H. et al. Dixon. Remote Application and Use of Real-Time Continuous Glucose Monitoring by Adults with Type 2 Diabetes in a Virtual Diabetes Clinic. Diabetes Technology & Therapeutics 2021; 23: 128-132
• 53 Polonsky WH, Layne JE, Parkin CG. et al. Impact of Participation in a Virtual Diabetes Clinic on Diabetes-Related Distress in Individuals With Type 2 Diabetes. Clinical diabetes : a publication of the American Diabetes Association 2020; 38: 357-362
• 54 Bahrmann A, Wörz E, Specht-Leible N. et al. Diabetes care and incidence of severe hypoglycemia in nursing home facilities and nursing services: The Heidelberg Diabetes Study. Z Gerontol Geriatr 2015; 48: 246-254
• 55 Mattishent K, Richardson K, Dhatariya K. et al. The effects of hypoglycaemia and dementia on cardiovascular events, falls and fractures and all-cause mortality in older individuals: A retrospective cohort study. Diabetes, obesity & metabolism 2019; 21: 2076-2085
• 56 Deutsche Diabetes Gesellschaft (DDG): S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. 2018
• 57 Kosjerina V, Carstensen B, Jørgensen ME. et al. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study. The Lancet Healthy Longevity 2021; 2: e561-e570
• 58 Ahlqvist E, Storm P, Käräjämäki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. The lancet Diabetes & endocrinology 2018; 6: 361-369
• 59 Hall H, Perelman D, Breschi A. et al. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol 2018; 16: e2005143
• 60 Bergenstal RM, Mullen DM, Strock E. et al. Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes. Journal of diabetes and its complications 2022; 36: 108106
• 61 Khunti K, Gomes MB, Pocock S. et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes, obesity & metabolism 2018; 20: 427-437
• 62 Reach G, Pechtner V, Gentilella R. et al. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes & metabolism 2017; 43: 501-511
• 63 Giugliano D, Maiorino MI, Bellastella G. et al. Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. Journal of endocrinological investigation 2019; 42: 495-503
• 64 Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes, obesity & metabolism 2018; 20: 488-496
• 65 Polonsky WH, Fisher L, Guzman S. et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543-2545
• 66 Peyrot M, Barnett AH, Meneghini LF. et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetic medicine : a journal of the British Diabetic Association 2012; 29: 682-689
• 67 Gerstein HC, Miller ME, Genuth S. et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. The New England journal of medicine 2011; 364: 818-828